FY2024 Earnings Forecast for InflaRx Issued By HC Wainwright

InflaRx (NASDAQ:IFRX) – Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for shares of InflaRx in a research note issued on Monday, November 11th. HC Wainwright analyst E. White now expects that the company will earn ($1.05) per share for the year, down from their previous estimate of ($0.97). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2024 earnings at ($0.31) EPS, FY2025 earnings at ($1.16) EPS and FY2026 earnings at ($1.13) EPS.

InflaRx Trading Up 13.2 %

NASDAQ:IFRX opened at $1.71 on Thursday. The stock has a market capitalization of $100.68 million, a P/E ratio of -1.58 and a beta of 1.57. InflaRx has a 1 year low of $1.17 and a 1 year high of $2.10. The firm has a 50 day moving average of $1.53 and a 200-day moving average of $1.51.

Hedge Funds Weigh In On InflaRx

An institutional investor recently raised its position in InflaRx stock. Ikarian Capital LLC lifted its holdings in InflaRx (NASDAQ:IFRX) by 2.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 704,987 shares of the company’s stock after buying an additional 16,383 shares during the quarter. Ikarian Capital LLC owned about 1.20% of InflaRx worth $1,086,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.